HUTCHMED Announces Key Managerial LTIP Vesting
TipRanks · 2d ago
Weekly Report: what happened at HCM last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at HCM last week (0408-0412)?
Weekly Report · 04/15 09:27
Weekly Report: what happened at HCM last week (0401-0405)?
Weekly Report · 04/08 09:29
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio, A Seattle-Suzhou ADC Biotech, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, for autoimmune and inflammatory dermatologic diseases. Shanghai's Visen Pharma announced plans to stage an IPO on the Hong Kong Exchange.
Seeking Alpha · 04/07 10:30
HUTCHMED to Unveil New Cancer Drug Data at AACR 2024
TipRanks · 04/05 11:00
HUTCHMED Says Initial Preclinical Data For HMPL-506 Novel, Highly Potent And Differentiated Menin-MLL Inhibitor For The Treatment Of Certain Types Of Acute Leukemia At AACR Congress 2024
Initial preclinical data will be presented for HMPL-506, a menin-MLL inhibitor for the treatment of certain types of acute leukemia. The drug shows stronger inhibitory potency than five other menin inhibitors in clinical development. A Phase I study is planned for the second half of 2024.
Benzinga · 04/05 09:18
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
New and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research Annual Meeting 2024. The meeting will take place on April 5-10, 2024 in San Diego, California.
Barchart · 04/05 03:30
Standard Biotools enters strategic engagement with Bristol Myers for expanded use of Somascan platform
Healthcare Standard Biotools enters strategic engagement with Bristol Myers for expanded use of Somascan platform. Standard BioTools Inc. Entered into a multi-year engagement with biopharmaceutical company Bristol Myers Squibb for use of the SomaScan Platform. Bristol Myers has been an early adopter of the protein-based platform.
Seeking Alpha · 04/03 20:10
New Hope in Advanced Endometrial Cancer Treatment
Hutchmed (China) Limited (HCM) has released an update. China's NMPA has accepted their New Drug Application with priority review for a groundbreaking combination treatment of advanced endometrial cancer. This marks the first regulatory filing for the fruquintinib and sintilimab combination.
TipRanks · 04/02 10:59
HUTCHMED (China) And Innovent's Endometrial Cancer Treatment Granted Priority Review By NMPA
NASDAQ · 04/02 05:16
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Barchart · 04/01 23:30
Weekly Report: what happened at HCM last week (0325-0329)?
Weekly Report · 04/01 09:29
HUTCHMED’s Savolitinib sNDA Under Review in China
TipRanks · 03/28 11:01
On Wednesday, HUTCHMED Announced Savolitinib sNDA Accepted in China For Treatment-Naïve Or Previously Treated Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
The supplemental New Drug Application for savolitinib has been accepted for review by the China National Medical Products Administration. If approved, the label indication for the drug will be expanded to include treatment-naïve patients in China. The drug is being developed for patients with lung cancer.
Benzinga · 03/28 08:55
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Barchart · 03/27 19:00
Weekly Report: what happened at HCM last week (0318-0322)?
Weekly Report · 03/25 09:30
HUTCHMED Advances Sovleplenib Trial in China
TipRanks · 03/22 10:59
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
HUTCHMED (China) Limited has initiated the registration stage of the Phase II/III clinical trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China. The company is a subsidiary of HUTCH MEDIA.
Barchart · 03/21 19:00
Hutchmed Is Turning Profitable
Hutchmed (China) Limited is a biopharmaceutical company with a market capitalization of $3 billion. The company's total revenue doubled to $838 million in 2023, driven by sales of the cancer drug FRUZAQLA. HCM delivered a profit of $100.8 million and has a strong cash position of over $880 million. In December, Tudor Invest Holdings upgraded HCM from a Hold to a Buy on expectations of the company turning profitable.
Seeking Alpha · 03/20 12:55
Webull provides a variety of real-time HCM stock news. You can receive the latest news about Hutchmed (China) Limited through multiple platforms. This information may help you make smarter investment decisions.
About HCM
HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.